Rapport reveals promising open-label study data for epilepsy pill, heads to Phase 3

Rapport Therapeutics' shares {$RAPP} jumped 170% at market open Monday after it posted topline mid-stage data indicating that its epilepsy pill can cut seizure frequency. However, the trial was small and ...